KR970705410A - 폐렴구균 감염에 대한 면역용 폐렴구균 다당류-재조합 뉴모리신 결합체 백신(pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections) - Google Patents

폐렴구균 감염에 대한 면역용 폐렴구균 다당류-재조합 뉴모리신 결합체 백신(pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections)

Info

Publication number
KR970705410A
KR970705410A KR1019970701180A KR19970701180A KR970705410A KR 970705410 A KR970705410 A KR 970705410A KR 1019970701180 A KR1019970701180 A KR 1019970701180A KR 19970701180 A KR19970701180 A KR 19970701180A KR 970705410 A KR970705410 A KR 970705410A
Authority
KR
South Korea
Prior art keywords
polysaccharide
pneumococcal
conjugate
oxidized
vaccine
Prior art date
Application number
KR1019970701180A
Other languages
English (en)
Other versions
KR100385411B1 (ko
Inventor
희수 케이 리
조셉 에스. 시 쿠오
Original Assignee
윌리엄 에이취. 캘넌
아메리칸 사이아나미드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리엄 에이취. 캘넌, 아메리칸 사이아나미드 캄파니 filed Critical 윌리엄 에이취. 캘넌
Publication of KR970705410A publication Critical patent/KR970705410A/ko
Application granted granted Critical
Publication of KR100385411B1 publication Critical patent/KR100385411B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

페렴구균의 협막 다당류로부터 유도된 산화 다당류 및 재조합적으로 발현되는 폐렴구균의 뉴모리신 단백질로 이루어진 면역원성 다당류-단백질 결합체가 생성된다. 뉴모리신은 산화 다당류와 결합하기 전에는 변독소화 되지 않는다. 면역원성 결합체는 폐렴구균의 협막 다당류 및 재조합 뉴모리신에 대한 항체 반응을 유도하고 폐렴구균-유발 질환에 대해 면역화시키기 위한 백신으로서 사용된다.

Description

폐렴구균 감염에 대한 면역용 폐렴구균 다당류-재조합 뉴모리신 결합체 백신(PNEUMOCOCCAL POLYSACCHARIDE-RECOMBINANT PNEUMOLYSIN CONJUGATE VACCINES FOR INNUNIZATION AGAINST PNEUMOCOCCAL INFECTIONS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (12)

  1. (a) 폐렴구균(Streptococcal, pneumoniae)의 협막 다당류로부터 유도된 산화 다당류, 및 (b) 재조합적으로 발현되고, 산화 다당류와 결합하기에 앞서 변독소화되지 않거나 부위-특이성 돌연변이생성에 의해 생성되지 않는, 폐렴구균의 뉴모리신 단백질을 포함하는 면역원성 다당류-단백질 결합체.
  2. 제1항에 있어서, 폐렴구균의 협막 다당류가 유형 14 또는 18C로부터 유도되는 결합체.
  3. 제1항에 있어서, 재조합적으로 발현되는 뉴모리신이 이. 콜라이에서 발현되는 결합체.
  4. 제3항에 있어서, 재조합적으로 발현되는 뉴모리신이 pGEX-PL 18C로 명명된 플라스미드(ATCC69654) 및 pGEX-PL 18C/20로 명명된 플라스미드 (ATCC69655)로 이루어진 그룹중에서 선택된 플라스미드를 포함하는 SCS1으로 명명된 이. 콜라이 균wn에서 발현되는 결합체.
  5. 제1항에 있어서, 재조합적으로 발현된 뉴모리신이 폐렴구균의 협막 다당류로부터 유도된 산화 다당류와 결합하기에 앞서 스페이서와 먼저 결합하는 결합체.
  6. 제5항에 있어서, 스페이서가 아디프산 디히드라지드(ADH) 및 6-아미노카 프로산으로 이루어진 그룹중에서 선택되는 결합체.
  7. 제1항의 면역원성 결합체를 포함하는 백신.
  8. 제7항에 있어서, 하나 이상의 면역학적으로 허용되는 희석제, 담체 또는 보조제를 추가로 포함하는 백신.
  9. 제7항에 있어서, 적어도 두개의 면역원성 결합체와 폐렴구균의 상이한 유형의 협막 다당류로부터 유도된 산화 다당류와의 혼합물을 포함하는 백신.
  10. 온혈 동물에 면역원량의 제7항의 백신 투여를 포함하는, 온혈 동물에서 폐렴구균의 협막 다당류에 대한 항체 반응을 유도하는 방법.
  11. 근육내, 복강내 또는 피하 주사에 의해 면역원량으로 제7항의 백신을 온혈 동물에 투여하는 것을 포함하는, 온혈 동물에서 폐렴구균-유발 질환에 대해 면역화시키는 방법.
  12. 다당류를 약산으로 처리하여 다당류를 분자량 10,000 내지 600,000달톤으로 부분적으로 해중합시키고, 이어서, 부분적으로 해중합된 다당류를 나트륨 페리오데이트, 칼륨 페리오데이트 및 페리오드산으로 이루어진 그룹중에서 선택된 페리오데이트로 처리하고, 발열물질-비함유수에 대해 투석시키거나 겔 여과 컬럼 크로마토 그래피로 정제한 다음, 산화 다당류를 원심분리시키고 동결건조시키는 단계를 포함하는 폐렴구균의 유형 18C다당류의 산화 단편을 제조하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970701180A 1994-08-24 1995-08-10 폐렴구균감염에대한면역용폐렴구균다당류-재조합뉴모리신결합체백신 KR100385411B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/295,305 US5565204A (en) 1994-08-24 1994-08-24 Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US08/295,305 1994-08-24

Publications (2)

Publication Number Publication Date
KR970705410A true KR970705410A (ko) 1997-10-09
KR100385411B1 KR100385411B1 (ko) 2003-12-11

Family

ID=23137126

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970701180A KR100385411B1 (ko) 1994-08-24 1995-08-10 폐렴구균감염에대한면역용폐렴구균다당류-재조합뉴모리신결합체백신

Country Status (14)

Country Link
US (1) US5565204A (ko)
EP (1) EP0778781B1 (ko)
JP (1) JP3927233B2 (ko)
KR (1) KR100385411B1 (ko)
AT (1) ATE198051T1 (ko)
AU (1) AU704450B2 (ko)
CA (1) CA2198251C (ko)
DE (1) DE69519634T2 (ko)
DK (1) DK0778781T3 (ko)
ES (1) ES2152421T3 (ko)
GR (1) GR3035081T3 (ko)
IL (1) IL115047A (ko)
PT (1) PT778781E (ko)
WO (1) WO1996005859A1 (ko)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6165762A (en) 1996-08-16 2000-12-26 Smithkline Beecham Corporation DNA encoding adenine phosphoribosyltransferase from Streptococcus pneumoniae
DE69737125T3 (de) * 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae-Antigene und Impfstoffe
EP0977764A4 (en) * 1997-03-26 2001-04-11 Brigham & Womens Hospital PROCESS FOR PRODUCING SACCHARIDE FRAGMENTS
CA2288267A1 (en) * 1997-04-24 1998-10-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US6676943B1 (en) 1997-04-24 2004-01-13 Regents Of The University Of Minnesota Human complement C3-degrading protein from Streptococcus pneumoniae
WO1999003884A2 (en) * 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US5882898A (en) * 1997-08-29 1999-03-16 Smithkline Beecham Corporation Streptococcus pneumoniae polynucleotides which encode folyl-polyglutamate synthetase (FPGS) polypeptides
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6165763A (en) * 1997-10-30 2000-12-26 Smithkline Beecham Corporation Ornithine carbamoyltransferase
US5861281A (en) 1997-10-30 1999-01-19 Smithkline Beecham Corporation Lacc
US6274719B1 (en) * 1998-04-24 2001-08-14 Smithkline Beecham Corporation Gcp
ATE278420T1 (de) * 1998-07-14 2004-10-15 Wyeth Corp Monophosphoryllipid a enthaltende adjuvans- und impfstoffzusammensetzungen
US6268177B1 (en) * 1998-09-22 2001-07-31 Smithkline Beecham Corporation Isolated nucleic acid encoding nucleotide pyrophosphorylase
WO2000026359A1 (en) * 1998-11-04 2000-05-11 Smithkline Beecham Corporation ftsX
GB9906437D0 (en) * 1999-03-19 1999-05-12 Smithkline Beecham Biolog Vaccine
HU228499B1 (en) * 1999-03-19 2013-03-28 Smithkline Beecham Biolog Streptococcus vaccine
WO2001007465A1 (en) * 1999-07-22 2001-02-01 Smithkline Beecham Corporation Ga1R
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
DE60144198D1 (de) * 2000-12-28 2011-04-21 Wyeth Llc Rekombinantes schutzprotein aus streptococcus pneumoniae
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
JP4740738B2 (ja) 2002-08-02 2011-08-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
US7301554B2 (en) * 2002-09-20 2007-11-27 Ricoh Company, Ltd. Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
BR0315767A (pt) 2002-11-01 2005-09-06 Glaxosmithkline Biolog Sa Composição imunogência, método para fabricar uma vacina, kit, vacina, recipiente com uma superfìcie interna repelente à água, e, método para preservar uma composição que compreende ipv e um agente estabilizador
CA2504938C (en) * 2002-11-07 2011-10-11 Synergy America, Inc. Compositions and methods for treating or preventing pneumococcal infection
CN101818185B (zh) 2003-03-13 2016-05-25 葛兰素史密丝克莱恩生物有限公司 纯化细菌溶细胞素的方法
EP1651261B1 (en) * 2003-08-06 2014-10-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polysaccharide-protein conjugate vaccines
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
CA2539715C (en) 2003-10-02 2015-02-24 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
GB0502096D0 (en) * 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc A multivalent pneumomuroral protein-polysaccharide conjugate preparation
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP3020411A1 (en) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
UA92782C2 (ru) 2006-01-17 2010-12-10 Арне Форсгрен Новый поверхностный белок haemophilus influenzae (белок е; ре)
WO2007116409A2 (en) 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
WO2007144647A2 (en) * 2006-06-15 2007-12-21 Timothy John Mitchell Adjuvant compositions
ZA200900899B (en) * 2006-08-07 2010-07-28 Harvard College Protein matrix vaccines and methods of making and administering such vaccines
EP2056871B1 (en) 2006-08-07 2017-11-15 President and Fellows of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BRPI0810211A2 (pt) 2007-04-13 2014-10-21 Univ Oklahoma Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
JP5666310B2 (ja) * 2008-12-03 2015-02-12 株式会社カネカ ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
BR112012022688A2 (pt) 2010-03-10 2018-05-22 Glaxosmithkline Biologicals Sa proteína de fusão, vesícula da membrana externa isolada, polinucleotídeo, composição farmacêutica, vacina, método para tratamento ou prevenção de infecção ou doença por neisseria, uso e método para fabricar uma proteína de fusão
AU2011294776B2 (en) 2010-08-23 2016-02-04 Wyeth Llc Stable formulations of Neisseria meningitidis rLP2086 antigens
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
CA2809758C (en) 2010-09-10 2021-07-13 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
ITMI20111182A1 (it) 2011-06-28 2012-12-29 Canio Buonavoglia Vaccino per coronavirus canino
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
KR101315599B1 (ko) 2011-10-25 2013-10-10 건국대학교 산학협력단 폐렴균점막다당질 유형14 （ｃｐｓ１４）와 호스래디시 퍼옥시다제의 당단백중합체
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
EP4043029A1 (en) 2012-03-09 2022-08-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
ES2685894T3 (es) 2013-03-08 2018-10-15 Pfizer Inc. Polipéptidos de fusión inmunogénicos
MX369534B (es) 2013-09-08 2019-11-11 Pfizer Composiciones de neisseria meningitidis y sus metodos.
AU2015208820B2 (en) * 2014-01-21 2020-05-14 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
MX2017006625A (es) 2014-11-21 2018-01-15 Univ Oklahoma Mutantes de neumolisina y metodos de uso de los mismos.
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
WO2017031431A1 (en) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Lipidated psa compositions and methods
EP3484441A4 (en) 2016-07-15 2020-03-18 President and Fellows of Harvard College GLYCOLIPID COMPOSITIONS AND METHODS OF USE
CN118662649A (zh) 2016-12-30 2024-09-20 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
MX2019009011A (es) 2017-01-31 2019-09-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos.
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
WO2018227177A1 (en) 2017-06-10 2018-12-13 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
EP3900739A1 (en) * 2020-04-21 2021-10-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Synthetic streptococcus pneumoniae saccharide conjugates to conserved membrane protein
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4242501A (en) * 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4686102A (en) * 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
IL92816A0 (en) * 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
CA2198251C (en) 2007-06-12
DE69519634D1 (de) 2001-01-18
EP0778781B1 (en) 2000-12-13
DK0778781T3 (da) 2001-01-02
CA2198251A1 (en) 1996-02-29
IL115047A0 (en) 1995-12-08
WO1996005859A1 (en) 1996-02-29
DE69519634T2 (de) 2001-06-13
AU704450B2 (en) 1999-04-22
US5565204A (en) 1996-10-15
AU3363695A (en) 1996-03-14
ATE198051T1 (de) 2000-12-15
GR3035081T3 (en) 2001-03-30
JP3927233B2 (ja) 2007-06-06
KR100385411B1 (ko) 2003-12-11
ES2152421T3 (es) 2001-02-01
IL115047A (en) 2005-08-31
JPH10504717A (ja) 1998-05-12
PT778781E (pt) 2001-03-30
EP0778781A1 (en) 1997-06-18

Similar Documents

Publication Publication Date Title
KR970705410A (ko) 폐렴구균 감염에 대한 면역용 폐렴구균 다당류-재조합 뉴모리신 결합체 백신(pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections)
Schneerson et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
KR102608081B1 (ko) 폴리사카라이드-단백질 접합체를 포함하는 다가 폐렴구균 백신 조성물
US4356170A (en) Immunogenic polysaccharide-protein conjugates
CA1276109C (en) Immunogenic conjugates
US5204098A (en) Polysaccharide-protein conjugates
US5445817A (en) Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
Wessels et al. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
US6007818A (en) Oligosaccharide derived from an antigenic polysaccharide obtained from a pathogenic agent
EP0598818B1 (en) Escherichia coli o-polysaccharide-protein conjugate vaccine
JP6276227B2 (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ．ａｕｒｅｕｓ５型および８型莢膜多糖の結合体
BR9507400A (pt) Composições imunogénicas de polissacaridio streptococal grupo a e processos
Michon et al. Multivalent pneumococcal capsular polysaccharide conjugate vaccines employing genetically detoxified pneumolysin as a carrier protein
US20060134141A1 (en) Glycoconjugate vaccines containing peptidoglycan
CA2145397A1 (en) Group b streptococcus type ii and type v polysaccharide-protein conjugate vaccines
Verheul et al. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates
Jennings Further approaches for optimizing polysaccharide-protein conjugate vaccines for prevention of invasive bacterial disease
Schneerson et al. Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin
Shen et al. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization
EP0894008B1 (en) Method of producing immunogenic products and vaccines
Singh et al. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi
Crowley-Luke et al. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines
Jacques et al. Escherichia hermannii (ATCC 33651) polysaccharide-protein conjugates: comparison of two conjugation methods for the induction of humoral responses in mice

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070406

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee